v3 Template
T

Tribune Therapeutics

Biopharmaceutical ~320 employees
Founded
--
Employees (Est.)
~320
16 leaders known
Total Funding
$124.8M
Funding Rounds
4
Last Funding
2025-03-26

About Tribune Therapeutics

Tribune Therapeutics is a preclinical biopharmaceutical company focused on developing novel medicines to treat fibrosis across various tissues and causes. Inspired by nature and fueled by insight, their mission is to stop the cycle of scar formation by targeting multiple drivers of fibrosis using natural mechanisms.

Products & Services

TRX-44:An advanced candidate that interferes with activated pro-fibrotic CCN domains to block fibrotic signaling, showing strong anti-fibrotic effects in animal models of lung and kidney fibrosis.
Pipeline of Novel Medicines:A range of therapies targeting fibrosis regardless of cause, tissue, or diagnosis, by interrupting signaling of key CCN protein family members like CCN2 (CTGF).

Specialties

Fibrosis Treatment Anti-Fibrotic Therapies CCN Protein Signaling Preclinical Drug Development

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Series A
T: -
FT: Series A
A: 23000000
MR: -
FA: €23 million
FAN: 23000000
D: 2025-03-26
FD: 2025-03-26
7 investors
2 RT: Series A
T: -
FT: Series A
A: 24840000
MR: -
FA: €23 million
FAN: 24840000
D: 2025-03-26
FD: 2025-03-26
7 investors
3 RT: Seed and Series A
T: -
FT: Seed and Series A
A: 39960000
MR: -
FA: EUR 37 Million
FAN: 39960000
D: 2025-03-26
FD: 2025-03-26
7 investors
4 RT: Seed and Series A
T: -
FT: Seed and Series A
A: 37000000
MR: -
FA: EUR 37 million
FAN: 37000000
D: 2025-03-26
FD: 2025-03-26
7 investors
Series A Latest
2025-03-26
$23.0M
7 investors (Pro only)
Series A 2025-03-26
$24.8M
Seed and Series A 2025-03-26
$40.0M

View 3 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

G

Georg Vo Beiske

CEO

O

Ole J. Kaasbøll

Chief Scientific Officer (CSO)

B

Berthold Bödeker

CTO

M

Mathias Locher

Chief Development Officer (CDO)

J

Jonas Hansson

Board Member

B

Björn Odlander

Managing Partner at HealthCap

View 13 more team members with Pro

Unlock Full Team Directory

Recent News

Tribune Therapeutics Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Industries
Biopharmaceutical
Company Size
~320 employees (est.)

Similar Companies

Discover AI-powered company recommendations based on industry, funding, and team profiles.

Upgrade to Pro

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro